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1  | INTRODUC TION
As demonstrated by the 2012 discovery of the Middle East 
Respiratory Syndrome coronavirus (MERS- CoV) in Saudi Arabia,1 
human coronaviruses continue to emerge and may become 
significant public health problems. MERS- CoV followed closely on 
the 2003 identification of severe acute respiratory syndrome coro-
navirus (SARS- CoV).2 Both viruses originated from animal reservoirs 
and cause significant mortality.2-4 By contrast, 4 other human coro-
naviruses (HCoVs), 229E, HKU1, NL63, and OC43, already circulate 
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Background: The prevalence, symptom course, and shedding in persons infected 
with the 4 most common human coronaviruses (HCoV)- 229E, HKU1, NL63, and 
OC43 are poorly described.
Objectives: We estimate their prevalence and associated symptoms among college 
students identified via a social network study design.
Patients/Methods: We collected 1- 3 samples (n = 250 specimens) from 176 partici-
pants between October 2012 and January 17, 2013: participants with acute respira-
tory infection (ARI; cough and body aches or chills or fever/feverishness) and their 
social contacts. Virus was detected using RT- PCR.
Results: 30.4% (76/250) of specimens tested positive for any virus tested, and 4.8% 
(12/250) were positive for 2 or more viruses. Human coronaviruses (HCoVs [22.0%; 
55/250]), rhinovirus (7.6%; 19/250), and influenza A (6.4%; 16/250) were most preva-
lent. Symptoms changed significantly over time among ARI participants with HCoV: 
the prevalence of cough and chills decreased over 6 days (P = .04, and P = .01, re-
spectively), while runny nose increased over the same period (P = .02). HCoV- NL63 
was the most frequent virus detected 6 days following symptom onset (8.9%), fol-
lowed by rhinovirus (6.7%).
Conclusions: During a 3- month period covering a single season, HCoVs were com-
mon, even among social contacts without respiratory symptoms; specific symptoms 
may change over the course of HCoV- associated illness and were similar to symp-
toms from influenza and rhinovirus.
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globally, but generally have low fatality rates.5-10 These 4 HCoVs 
also are believed to be derived from zoonotic sources, including bats 
(NL63, 229E), dromedary camels (299E), or cattle (OC43), although 
the origins of HKU1 remain uncertain.11-14
The 4 HCoVs are linked to common cold symptoms,9,10,15,16 while 
HCoV- HKU1 has less definitively been linked to gastrointestinal 
symptoms.17,18 HCoV- HKU1 and HCoV- NL63 can cause severe dis-
eases, including bronchitis, bronchiolitis, and/or croup among pedi-
atric and adult hospitalized patients.5,7,8,19-21 However, due to the 
relatively mild course of illness in the majority of otherwise healthy 
individuals, these 4 HCoVs are thought to be underreported.22
Our current understanding of the epidemiology of HCoV- 229E, 
HCoV- HKU1, HCoV- NL63, and HCoV- OC43 outside of clinics is 
extremely limited. The prevalence, severity, and co- occurrence of 
HCoVs with other respiratory viruses are not yet established.4 Data 
are primarily from outbreak reports, case studies, and clinical stud-
ies focusing predominantly on children.5,6,8,15,18 Here, we begin to 
address this gap by estimating the prevalence, shedding duration, 
symptom progression, and codetection with other respiratory vi-
ruses of HCOV- 229E, HKU1, NL63, and OC43 among a cohort of 
college- aged students.
2  | METHODS
We collected demographic, clinical data, and throat and anterior 
nasal specimens from students as part of a previously described 
large social network study of acute respiratory infection (ARI) among 
university students.23 Briefly, a total of 590 students living in one of 
6 on- campus residence halls were recruited through a chain referral 
method between October 2012 and January 17, 2013. All partici-
pants were asked to identify recent social contacts through search-
ing a list of enrolled contacts or through suggestions based on the 
underlying social network on a weekly online survey. For a 10- week 
period from January 17 until April 9, 2013, participants experiencing 
respiratory symptoms were asked to complete an online screening 
survey to self- report illness symptoms.
Participants reporting symptoms meeting the ARI case definition 
(cough plus at least one of the following: body aches, chills, or fever/
feverishness) were scheduled to provide up to 3 specimens over a 6- 
day period following ARI onset. In order to reduce the likelihood that 
any 2- illness episodes were linked to the same etiology, symptom- 
onset dates were required to be at least 2 weeks apart for an ARI 
participant to provide more than one set during the study period. 
This allowed us to consider each illness episode as an independent 
event.
2.1 | Social contacts
Once an ARI case was identified through our online screening sur-
vey, an email was automatically sent out to the individual’s network 
contacts, inviting presumed “healthy” social contacts to provide 
a specimen. The social network was identified through a list of 
contacts that each enrollee generated over the course of the study. 
Social contacts were eligible if: (i) they had recent face- to- face con-
tact within the previous calendar week with an ARI participant and 
(ii) were not an ARI participant during the previous 2 weeks. Social 
contacts that elected to provide specimens were scheduled for up to 
3 specimen collections.
Although healthy social contacts were not experiencing ARI 
when they were asked to provide a specimen, some of the social 
contacts reported symptoms of illness, such as cough or sneezing, 
at the time of specimen collection. Changes in symptoms among 
social contacts were calculated as the time from the first specimen 
collection to illness onset. Any social contact symptomatic on any 
one or more of the specimen collection days was defined as a “social 
contact with symptoms.” Any social contact remaining healthy on 
specimen collection days 0, 3, and 6 was defined as an “asymptom-
atic social contact.”
The University of Michigan’s Institutional Review Board (IRB) 
(HUM00054432) approved the study protocol, and the Centers for 
Disease Control and Prevention’s Human Subjects Research Office 
reviewed and approved deferral to the University of Michigan’s IRB.
2.2 | Symptom assessment
All participants providing specimens reported information on 13 
acute symptoms: abdominal pain, body aches, chills, cough, diar-
rhea, earache, feverishness, headache, nasal congestion, runny nose, 
sneezing, sore throat, and vomiting. Symptoms were collected using 
a standardized questionnaire administered by trained staff during 
the sample collection visit, and severity was reported as follows: not 
present, mild, moderate, or severe.
2.3 | Specimen collection and testing
For each ARI illness participant and invited social contact, we aimed 
to collect up to 3 samples from each study participant as follows:
2.3.1 | ARI participants
Day 0 specimen—within 24 hours of illness onset.
Day 3 specimen—between 25 and 96 hours after illness onset.
Day 6 specimen—between 97 and 144 hours after illness onset.
2.3.2 | Social contacts
Day 0 specimen—time of first specimen collected, as close to illness 
onset of ARI contact as possible.
Day 3 specimen—approximately 72 hours after initial specimen 
collection.
Day 6 specimen—approximately 144 hours after initial specimen 
collection.
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If a social contact reported symptoms consistent with our ARI 
definition, either through the online screening survey or during 
specimen collection, they were considered an ARI participant and 
their next scheduled specimen was considered a day 0 ARI speci-
men. The collection of any combination of day 0, day 3, and day 6 
specimens for any participant was defined as a “set” of specimens.
Trained staff collected specimens at each participant’s residence. 
Swabs were taken from 2 locations: the anterior nares and along the 
uvula. Both specimens were placed in Copan Universal Transport 
Media (Copan, Murrieta, California) and then stored at −70°C prior 
to testing.
All specimens were tested for 13 respiratory viruses: corona-
viruses 229E, HKU1, NL63, and OC43; adenovirus; human metap-
neumovirus (hMPV); influenza A and B; parainfluenza 1, 2, and 3; 
rhinovirus; and respiratory syncytial virus (RSV). For all viruses ex-
cept influenza A/B, aliquots from the throat and nasal swab were 
combined prior to testing. Influenza A/B testing was performed sep-
arately on throat and nasal swabs, and participants were considered 
positive for influenza if either swab tested positive.
The number of specimens collected per episode ranged from 1 
to 3 per set. For each illness episode, participants and each of their 
social contacts received an incentive of $15 for their first specimen, 
$20 for their second, and $25 for their third specimen within a col-
lection period.
Tests for all respiratory viruses were performed in the lab-
oratory using real- time reverse transcriptase polymerase chain 
reaction (RT- PCR). Primers and probes were developed by the 
Centers for Disease Control and Prevention (CDC) and ob-
tained from the Division of Viral Disease, Gastroenteritis, and 
Respiratory Viruses and the Influenza Division. Additional infor-
mation about the RT- PCR process and RNA/DNA extraction can 
be found elsewhere.24 We assessed the type and number of viral 
pathogens in each of the day 0, 3, and 6 specimens. A partici-
pant was considered positive for a particular virus (or viruses) if 
at least one of the 3 specimens within an illness episode had a 
positive RT- PCR result.
2.4 | Statistical analysis
We used Fisher’s exact tests and t tests to compare demographic 
differences between study participants providing and not providing 
specimens, as well as the virus prevalence between 3 groups: (i) ARI 
participants, (ii) social contacts with symptoms, and (iii) healthy so-
cial contacts. Symptoms were analyzed as present or absent, except 
for cough, which, as a required symptom for the ARI case definition, 
was defined as absent/mild compared to moderate/severe. To assess 
changes in symptoms over time, we compared the proportion of par-
ticipants who reported each symptom on day 0, 3, and 6 for each ill-
ness episode, testing for trends by virus with the Cochran- Armitage 
test. We assessed the change in illness symptoms over the 6- day 
period separately for ARI participants (with a defined symptom- 
onset date) and social contacts with symptoms (with no defined 
symptom- onset date). Due to sample size constraints, the 4 human 
coronaviruses were combined for symptom analysis. All statistical 
analyses were calculated using SAS 10.1 (Cary, NC).
3  | RESULTS
Of the 590 enrolled participants, 176 (29.8%) provided speci-
mens as an ARI participant, a social contact, or as both an ARI 
participant and social contact. A total of 250 sets, the collection 
of 1- 3 specimens over an illness episode, were collected: 81 of 176 
(46.0%) participants provided 96 sets of specimens after meeting 
the ARI case definition; 70 od 176 (39.8%) participants provided 
88 sets of specimens as social contacts; and 25 of 176 participants 
(14.2%) provided 66 sets of specimens (31 sets as an ARI case and 
35 sets as social contacts); 115 ARI reports were eligible for speci-
men collection, of those 96 of 115 (83.5%) provided a specimen. 
A mean of 1.6 specimens was collected per set. Compared to en-
rolled students who did not report ARI or did not provide speci-
mens as a social contact, those providing specimens were slightly 
older (19.5 years vs 19.1 years; P = .0006), had parents who were 
less well educated (P = .04), and were less likely to have received 
a 2011/12 seasonal influenza vaccine (37.7% vs 51.2%; P = .01; 
Table 1).
3.1 | Virus prevalence
Just over half (127/250; 50.8%) of the specimen sets were from ARI 
participants, 78 (31.2%) from social contact with symptoms, and 
45 (18.0%) from asymptomatic social contacts.  Overall, 76 (30.4%) 
of the 250 sets were positive for at least one of the 13 viruses in-
cluded in our assay; a total of 101 viruses were identified (11 dual 
infections, one triple infection). The overall prevalence of virus from 
ARI participants was 46.5%, compared to 28.3% for social contacts 
with symptoms (P = .01) and 13.3% for asymptomatic social con-
tacts (P < .001). The most common virus identified was HCoV- NL63 
(10.0%; 25/250), followed by rhinovirus (7.6%; 19/250), influenza 
A (6.4%; 16/250), and RSV (3.2%; 8/250). Influenza A was the only 
virus that appeared statistically significantly more frequent in ARI 
cases than social contacts with symptoms or asymptomatic social 
contacts (ARI participants 10.2% vs social contact with symptoms 
2.6%, P = .05); though not between ARI participants and asympto-
matic social contacts 2.2%, P = .12). No specimens tested positive 
for parainfluenza 2 (Table 2).
3.2 | Viral Codetection
The overall prevalence of codetection (ie, detection of >1 virus per 
illness episode) in our population was 4.8% (12/250; Table 3). There 
were 11 two- virus codetections and one triple codetection in our 
population (positive for HCoV- HKU1, influenza A, and rhinovirus). 
Rhinovirus occurred most frequently as a codetected agent (8 of 12 
specimens; 66.7%), while HCoV- NL63 was present in 50% of the 
codetected specimens (6/12). The viral positive counts in any one 
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group were too small to draw conclusions about the statistical as-
sociations between codetection and clinical symptoms.
3.3 | Persistence of virus shedding over time
Among ARI participants, the prevalence of all viruses detected 
decreased from time of symptom onset to follow- up. Influenza A 
(16.9%) was the most frequently detected virus on the day of illness 
onset, followed by HCoV- NL63 (15.3%). Human coronavirus NL63 
was the most frequent virus detected 6 days following illness onset 
(8.9%), followed by rhinovirus (6.7%). Parainfluenza viruses 1 and 2 
were not detected in any specimens collected from ARI participants 
(Table 4).
3.4 | Symptoms present during specimen collection
Of the 127 participants with ARI, 56 provided a specimen on day 
0, 98 provided a specimen on day 3, and 90 provided a specimen 
on day 6. The most frequent symptoms on day 0 were moderate/
severe cough (87.5%) and sore throat (83.9%). By day 3, the most 
frequent symptoms were moderate/severe cough (80.6%), nasal 
congestion (73.5%), and runny nose (72.4%). Finally, 6 days following 
TABLE  2 Prevalence of RT- PCR viral detection among 176 participants with 250 specimen sets using symptom status from the eX- FLU 
study in the university setting
Identified virus
ARI participanta
n = 127 (%)
Social contacts
P- valueb: ARI vs SC 
with symptoms
P- value: ARI vs 
asymptomatic SC
With symptoms 
n = 78 (%)
Asymptomatic 
n = 45
HCoV- 229E 5 (3.9) 2 (2.6) 1 (2.2) .71 1.00
HCoV- HKU1 1 (0.8) 2 (2.6) 0 (0.0) .56 1.00
HCoV- NL63 17 (13.4) 6 (7.7) 2 (4.4) .26 .16
HCoV- OC43 4 (3.1) 1 (1.3) 0 (0.0) .65 .57
Influenza A 13 (10.2) 2 (2.6) 1 (2.2) .05 .12
Influenza B 2 (1.6) 0 (0.0) 0 (0.0) .53 1.00
Adenovirus 2 (1.6) 1 (1.3) 0 (0.0) 1.00 .00
Human 
metapneumovirus
4 (3.1) 1 (1.3) 1 (2.2) .65 1.00
Parainfluenza 1 0 (0.0) 1 (1.3) 0 (0.0) .38 - 
Parainfluenza 2 0 (0.0) 0 (0.0) 0 (0.0) - - 
Parainfluenza 3 1 (0.8) 4 (5.1) 0 (0.0) .07 1.00
Respiratory syncytial 
virus
6 (4.7) 2 (2.6) 0 (0.0) .71 .34
Rhinovirus 13 (10.2) 4 (5.1) 2 (4.4) .30 .36
Any detected virus 59 (46.5) 22 (28.2) 6 (13.3) .01 .00006
aARI, acute respiratory illness consists of a cough plus at least one of the following: body aches, chills, and feverishness.
bP- value calculated using Fisher’s exact test.
Participants providing 
specimens (N = 176)
Participants not providing 
specimens (N = 414) P- value
Male 75 (42.6) 160 (41.9) .87
Age; Mean, SD 19.5 (1.2) 19.1 (0.9) .0009
Race
White 110 (64.7) 254 (68.7) .36
Black 13 (7.7) 34 (9.2)
Other 47 (27.7) 82 (22.2)
Parental education
<College 43 (25.0) 62 (16.7) .04
College 49 (28.5) 99 (26.6)
>College 80 (46.5) 211 (56.7)
Seasonal influenza 
vaccination 2012- 13
58 (37.7) 104 (51.2) .01
TABLE  1 Demographic Information for 
the 590 participants enrolled in the 
eX- FLU study
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illness onset, the most frequent symptoms were nasal congestion 
and runny nose (both 73.3%; Figure 1A).
Of the 78 social contacts with symptoms, 78 provided a spec-
imen on day 0, 67 on day 3, and 60 on day 6. The most frequent 
symptoms across the 6- day specimen collection time frame were 
runny nose (43.4% on day 0, 43.3% on day 3, and 50.0% on day 6) 
and nasal congestion (39.5% on day 0, 41.8% on day 3, and 45.0% on 
day 6; Figure 1B).
Looking over all the specimens collected in a set, 67.2% (203 of 
302 social contact specimens) of specimens collected from social 
contacts were associated with at least one symptom and 32.5% (98 
of 302 social contact specimens) were associated with no symptoms. 
3.5 | Change in symptoms over time
Among ARI participants with HCoV and multiple specimens (n = 19), 
the most common symptom within 24 hours of symptom onset was 
moderate/severe cough (12/12; 100%), followed by sore throat 
(11/12; 91.7%) and nasal congestion (9/12; 75.0%). Three days fol-
lowing symptom onset, moderate/severe cough (17/18; 94.4%) and 
sore throat (15/18; 83.3%) were the most common symptoms. Six 
days following symptom onset, the most common symptoms among 
ARI patients with HCoV were runny nose (16/17; 94.1%) and nasal 
congestion (14/17; 82.4%). Moderate/severe cough (P = .04), chills 
(P = .01), and headache (P = .03) decreased in prevalence from day 
0 to day 6. Only the reports of rhinitis (P = .02) increased over the 
6- day period (Figure 2A).
For ARI patients with influenza A and multiple specimens 
(n = 12), moderate/severe cough was the most prevalent symptom 
during the illness episode, followed by sore throat on day 0 and nasal 
congestion and runny nose on days 3 and 6 of the illness. Body aches 
(P = .02) and feverishness (P = .02) were the only symptoms with a 
significant difference in the prevalence of symptoms over time 
(Figure 2B).
Among ARI participants with rhinovirus and multiple speci-





syncytial virus Rhinovirus229E NL63 OC43
HCoV- 229E - 2 0 0 0 1
HCoV- NL63 - 0 1 1 2
HCoV- OC43 - 0 0 1





aOne specimen tested positive for HCoV- HKU1, influenza A, and rhinovirus.
TABLE  3 Frequency of 12 laboratory- 
identified codetected viruses within a 
single specimen among 250 specimen sets 
collected from the eX- FLU study in the 
university setting
TABLE  4 Persistence of virus detection by RT- PCR among 127 specimen sets from participants with ARIa from the ex- FLU study in the 
university setting
Identified virusb
Day 0 (n = 59) Day 3 (n = 98) Day 6 (n = 90)
Viral positive % Positive Viral positive % Positive Viral positive % Positive
HCoV- 229E 2 3.4 4 4.1 1 1.1
HCoV- HKU1 1 1.7 0 0.0 0 0.0
HCoV- NL63 9 15.3 15 15.3 8 8.9
HCoV- OC43 2 3.4 2 2.0 3 3.3
Influenza A 10 16.9 10 10.2 3 3.3
Influenza B 2 3.4 1 1.0 1 1.1
Adenovirus 2 3.4 1 1.0 1 1.1
Human 
metapneumovirus
0 0.0 2 2.0 2 2.2
Parainfluenza 3 0 0.0 1 1.0 1 1.1
Respiratory syncytial 
virus
3 5.1 4 4.1 3 3.3
Rhinovirus 7 11.9 10 10.2 6 6.7
aARI, acute respiratory illness is defined as a cough plus at least one additional symptom: body aches, chills, and feverishness.
bNo ARI participants tested positive for parainfluenza 1 or parainfluenza 2.
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collection times. Runny nose was the second most common symp-
tom, decreasing over the illness period from 100% on day 0 to 71.4% 
6 days after symptom onset; there were no significant changes in 
the prevalence of symptoms over time among ARI participants with 
rhinovirus (Figure 2C).
Symptoms among social contacts were compared at day 0, 3, and 
6 for HCoV (n = 9 participants), as this was the most prevalent type 
of virus identified in this group. Moderate/severe cough, nasal con-
gestion, and sore throat were the most frequent symptoms on day 
0 and day 3 of specimen collection. Six days after the initial speci-
men collection, nasal congestion (37.5%; 3/8) was the most common 
F IGURE  1 A, Frequency of symptoms present among acute 
respiratory infectiona participants (N = 127) on day 0 (n = 56 
specimens), day 3 (n = 98 specimens), and day 6 (n = 90 specimens). 
B, Frequency of symptoms present among social contacts with 
symptoms (N = 78) on day 0 (n = 78 specimens), day 3 (n = 67 
specimens), and day 6 (n = 60 specimens) following the initial 
specimen collectiona. aCough is defined as moderate or severe vs 
mild or absent; all other symptoms were either present or absent
F IGURE  2 A, Frequency of symptoms present among 19 ARIa 
participants positive for at least one of the 4 human coronaviruses 
on day 0 (n = 12), day 3 (n = 18), and/or day 6 (n = 16) following 
illness onsetb,c. B, Frequency of symptoms present among 12 ARIa 
participants positive for influenza A on day 0 (n = 10), day 3 (n = 12), 
and/or day 6 (n = 10) following illness onsetb,c. C, Frequency of 
symptoms present among 9 ARIa participants positive for rhinovirus 
on day 0 (n = 7), day 3 (n = 8), and/or day 6 (n = 7) Following illness 
onsetb. aARI, acute respiratory illness defined as a cough plus 
at least one additional symptom: body aches, chills, and fever/
feverishness; bCough is defined as moderate or severe vs mild or 
absent; all other symptoms were either present or absent; cP- values 
calculated by the Cochran- Armitage test for trend over the day 0, 
3, and 6 specimens
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symptom, followed by sore throat (25%; 2/8) among HCoV- positive 
social contacts with symptoms. There were no symptoms with sig-
nificant changes in the prevalence over time among HCoV- positive 
social contacts with symptoms (Figure 3A).
4  | DISCUSSION
There are few prospective non- clinic- based studies describing the 
epidemiology of human coronaviruses 229E, HKU1, NL63, and 
OC43 and the changes in symptoms over time. Among the otherwise 
healthy young adults with ARI symptoms and a sample of their so-
cial contacts participating in this study during a single season, winter 
season, the prevalence of the 4 HCoVs combined was 19.7% among 
specimens from participants with ARI, 14.1% among social contacts 
with symptoms, and 6.7% among asymptomatic social contacts. 
Codetection of viruses was found in 12 specimens collected during 
the study period, including one triple codetection with HCoV- HKU1, 
influenza A, and rhinovirus. Influenza A was the most commonly 
detected virus among specimens collected from ARI participants, 
while HCoV- NL63 was the most frequent virus detected 6 days fol-
lowing illness onset. We found that moderate/severe cough, chills, 
and headache decreased in frequency over the 6- day period among 
students with HCoV infections, while runny nose increased in fre-
quency over the 6- day period; no similar frequency trends were 
observed among symptomatic social contacts with HCoV. While 
statistically significant differences were observed between patients 
providing specimens and participants not providing specimens in age 
and parental education, the significantly higher portion of patients 
not providing specimens with a seasonal influenza vaccination status 
is likely of concern for interpretation. The differences potentially 
suggest that receiving a vaccination decreased the likelihood of pro-
viding a specimen during our study, an area to note for future studies 
with a voluntary specimen collection component.
Our prevalence estimates are higher than estimates for a pre-
viously conducted study examining these 4 HCoVs in adult and as-
ymptomatic populations, potentially due to the close contact within 
the residence halls. In addition, our focus on ARI participants and 
their social contacts did not include individuals living in residence 
halls that did not have contact with an ARI participant. As such, our 
reported prevalence estimates among social contacts of ARI cases 
only are likely higher than they would be among a similar population 
without known ARI contact. In that retrospective study conducted 
over 9 years in São Paulo, Brazil, the prevalence of HCoVs tested 
by RT- PCR was 8% among 50 adults living in the community with 
influenza- like illness.25 An additional 50 asymptomatic adults were 
tested, and no positive HCoV specimens were detected. By contrast, 
we found that 6.7% of our asymptomatic contacts were positive for 
HCoVs. A household study that used similar RT- PCR methods con-
ducted over the same period as our study in southeast Michigan 
found a prevalence of 16% of HCoVs among individuals with ARI, 
but they did not examine the prevalence among non- ARI contacts.24
The high prevalence of HCoV, compared to the 12 other viruses 
in our testing panel, could be attributed to the timing of our study. 
Human coronaviruses are most frequently found during December 
through May, and long- term cohort studies suggest a cyclical pat-
tern in the presence of the 4 HCoVs over multiple years.26 However, 
without multiyear data, we are unable to determine whether the 
high prevalence of the HCoVs found was due to the cyclical nature 
of the virus or a result of testing ill individuals in close quarters. 
Unpublished data from a pilot study conducted among an indepen-
dent sample of 574 students followed from February to April 2011, 
resulted in few patients with ARI providing specimens (25), but we 
found a similar prevalence for HCoVs (16%; 4/25) in a similar young 
adult population (unpublished data available from corresponding au-
thor upon request). Further long- term annual studies of HCoVs in 
this community are needed to determine whether there is a seasonal 
effect or whether there is consistently higher prevalence among 
young adults in the university setting.
A total of 4.8% (12/250) of specimens were positive with more 
than one virus, and coronaviruses were found in 44% of the de-
tected codetection. Due to the small sample size, we were unable 
to assess which characteristics contributed to codetection, includ-
ing the one individual with 3 detected viruses. Other clinic- based 
studies, predominantly among children, have reported the occur-
rence of codetected viruses.6,8,27,28 However, studies outside of 
the clinical setting are rare. A study of healthy preschool- aged 
children in Australia reported twice the prevalence of codetection 
(56%), but their sample size was smaller (n = 18) and young chil-
dren tend to have higher rates of respiratory illness than young 
adults.29 These studies suggest that viral codetection is frequent 
in children. In contrast to these studies, our study designed al-
lowed for multiple samples taken from the same participant, 
F IGURE  3 Frequency of symptoms present among 9 social 
contact participants positive for at least one of the 4 human 
coronaviruses on day 0 (n = 9), day 3 (n = 9), and/or day 6 (n = 8) 
following initial specimen collectiona. aARI, acute respiratory illness 
defined as a cough plus at least one additional symptom: body 
aches, chills, and fever/feverishness; bCough is defined as moderate 
or severe vs mild or absent; all other symptoms were either present 
or absent; cP- values calculated by the Cochran- Armitage test for 
trend over the day 0, 3, and 6 specimens
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potentially increasing the likelihood that we would find individuals 
positive for multiple viruses. Overall, coviral infection appears to 
be less commons among university students compared to younger 
age individuals. More research is needed on adults to determine 
risk factors for coinfections among relatively healthy individuals 
with developed immune systems.
Human coronavirus- NL63 and rhinovirus had the highest propor-
tion of specimens positive after illness onset. A study examining the 
viral load of HCoV in children in a daycare setting found an average 
shedding duration of 6.4 days, with a range of 2.8- 10.1 days,30 while 
a previous rhinovirus challenge study reported patients shedding for 
at least 4 days, suggesting our findings are not unusual.31 However, 
unlike challenge studies, we were unable to definitely determine 
the date of infection or adequately sample among patients without 
symptoms. As such, the interpretation of symptoms over time and 
detection of virus over time are different for this community- based 
study rather than a controlled setting. These findings could influ-
ence infection control practices in schools, as well as elsewhere in 
the community. However, unlike challenge studies, we were unable 
to definitely determine the precise date of infection or sample every 
participant without symptoms. As such, the interpretation of symp-
toms over time and detection of virus over time are different for this 
community- based study rather than a controlled setting.
Our findings of persistently high prevalence of runny nose over 
the 6- day period in ARI cases with HCoV corresponds with common 
symptoms found in historical challenge studies of these viruses.26 
However, we were unable to find any other studies presenting a 
change in symptoms observed over time for the 4 globally circulating 
HCoVs outside of human challenge trials. The statistically significant 
decrease in cough, chills, and headache and increase in runny nose 
over the 6- day period for the HCoV observed in our study suggest 
that symptoms change significantly over the course of natural infec-
tion, making it difficult to delineate between viral etiologies associated 
with common ARI. The similarity of our findings with those of another 
study conducted in the region during the same season24 suggests that 
university students were under similar regional viral pressure. Due to 
the low level of severe illness, screening for these viruses in a univer-
sity setting does not seem necessary. However, it does seem likely that 
increased testing in the university setting, even among those with mild 
symptoms, would result in a high number of viruses detected. Future 
studies would help to confirm the results of this study over multiple 
seasons to assess long- term trends that were not observed during the 
current study, conducted over a single season.
Because we used a chain referral methodology for enrollment, our 
study population was not randomly recruited. It is unlikely that this 
would bias the estimates of viral prevalence among those with ARI; 
however, it is possible that the estimates for viral prevalence from 
healthy contacts may be elevated compared to the prevalence found 
in the general population. Additionally, prevalence estimates include 
samples that were taken at up to 3 time points within the first 6 days 
of illness, providing a greater opportunity to identify virus- positive 
samples compared to other study designs. Further, our testing for 
viruses was not exhaustive; the 13 viruses included were selected 
for their frequency of appearance as upper respiratory viruses in the 
population, as well as their clinical importance. However, additional 
respiratory viruses may have been present; as a result, the number 
of codetected viruses identified in this study is likely underestimated. 
Finally, seasonality may have influenced our findings. By recruiting 
and testing patients, January- April of 2012, we were more likely to 
see respiratory viruses compared to other circulating viruses.32
Human coronaviruses are common, even among those without 
respiratory symptoms, and specific symptoms may change over the 
course of an illness that can mirror symptoms ranging from influenza 
to rhinovirus. Larger studies in the community setting are needed 
to better understand the epidemiological and clinical significance of 
codetection. These studies may help to uncover important transmis-
sion characteristics that could inform measures for addressing more 
deadly coronavirus outbreaks.
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